|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:metformin
gptkb:dapagliflozin
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A10BD15
|
|
gptkbp:brand
|
dapagliflozin and metformin extended-release
|
|
gptkbp:contraindication
|
severe renal impairment
end-stage renal disease
hypersensitivity to dapagliflozin or metformin
|
|
gptkbp:drugClass
|
biguanide
SGLT2 inhibitor
|
|
gptkbp:form
|
extended-release tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xigduo XR
|
|
gptkbp:indication
|
improving glycemic control in adults with type 2 diabetes
|
|
gptkbp:manufacturer
|
gptkb:AstraZeneca
|
|
gptkbp:notRecommendedFor
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
|
|
gptkbp:pregnancyCategory
|
consult physician
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
urinary tract infection
lactic acidosis
genital mycotic infection
hypoglycemia (when used with insulin or sulfonylurea)
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:AstraZeneca_US
|
|
gptkbp:bfsLayer
|
6
|